Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders

NCT05792462 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

NMO Spectrum Disorder

Interventions

DRUG: Baricitinib

Sponsor

Tianjin Medical University General Hospital

Collaborators

[object Object]
[object Object]